SEC
AMPH icon

Seven Eight Capital’s Amphastar Pharmaceuticals AMPH Stock Holding History

Seven Eight Capital’s Portfolio AMPH Stock Details AMPH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-12,948
Closed -$801K – 599
2023
Q4 		$801K Buy
+12,948
New +$680K 0.09% 316

Other funds holding AMPH

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return
Neuberger Berman Group
Neuberger Berman Group New York $150B AUM 40.08% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Fuller & Thaler Asset Management
Fuller & Thaler Asset Management San Mateo, California $36.7B AUM 74.15% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
TD Asset Management
TD Asset Management Toronto, Ontario, Canada $115B AUM 41.58% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
EIP
Epoch Investment Partners New York $17.6B AUM 34.17% 1-Year Est. Return

Seven Eight Capital's AMPH Position: Q1 2024 in Review

Seven Eight Capital sold out of Amphastar Pharmaceuticals (AMPH) in Q1 2024, closing a stake of 12,948 shares — an estimated $801K sold.

Seven Eight Capital first reported a position in AMPH in Q4 2023 and held it in 1 quarter. The position peaked at $801K in Q4 2023. 270 funds tracked by Wall St. Rank hold AMPH as of Q1 2024.

  • Seven Eight Capital reported no remaining Amphastar Pharmaceuticals position as of Q1 2024 after selling out during the quarter.
  • Seven Eight Capital sold 12,948 Amphastar Pharmaceuticals shares in Q1 2024, an estimated $801K.
  • Seven Eight Capital first reported a position in Amphastar Pharmaceuticals in Q4 2023 and held it in 1 quarter.
  • Seven Eight Capital's Amphastar Pharmaceuticals position peaked at $801K in Q4 2023.
  • 270 funds tracked by Wall St. Rank held Amphastar Pharmaceuticals as of Q1 2024.

Based on Seven Eight Capital's 13F filing for Q1 2024, filed 13 May 2024.